Continuous Infusion Versus Intermittent IV Bolus of Cefazolin: Prevention of Surgical Site Infection During CABG Surgeries in Egyptian Patients.

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07658378

Enrollment

100

Registered

2026-06-22

Start date

2026-07-01

Completion date

2026-12-31

Last updated

2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Site Infection (SSI)

Keywords

cefazolin, continuous infusion, intermittent, surgical site infection, surgical prophylaxis, CABG

Brief summary

A randomized controlled trial on adults who underwent coronary artery bypass grafting (CABG) surgery. To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing surgical site infection in the CABG population. Eligible patients will be randomized using a block design into 2 groups: intervention and control. The intervention group will use continuous infusion of cefazolin (CI), while the control group will follow the traditional presurgical prophylaxis protocol of intermittent cefazolin doses (INT).

Interventions

DRUGCefazolin 2 g Infusion

To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing SSIs in a CABG (coronary artery bypass grafting) population.

DRUGCefazolin 2 GM Injection

To evaluate the effectiveness of intermittent (INT) cefazolin administration in preventing SSIs in a CABG (coronary artery bypass grafting) population.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Cardiothoracic ICU-admitted patients who underwent CABG on CPB.

Exclusion criteria

* Patients who require reoperation within 30 days. * Immunosuppressant patients. * Patients who are not adherent to the protocol time or dosing, either preoperatively, during, or postoperatively. * Pregnancy or breastfeeding. * Patients who refused to sign the informed consent.

Design outcomes

Primary

Measure	Time frame
Incidence of SSI	Within 3 months after surgery

Contacts

CONTACTHeba A Abdeen

hebabdeen89@gmail.com0201003403231

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 25, 2026